Research Shows Treatment Blocks Deadly Tick Disease with 100% Success

In the ongoing battle against tick-borne diseases in dogs, a groundbreaking study has brought hope to pet owners worldwide. The research focused on Babesia canis, a dangerous pathogen that poses a growing threat to canine health. The spotlight of this study was on Simparica Trio® (Zoetis), a treatment that combines sarolaner, moxidectin, and pyrantel in a powerful formula designed to prevent the transmission of B. canis.

The study involved 24 dogs, divided into groups where some received a placebo while others were treated with the minimum recommended dose of Simparica Trio. The dogs were then exposed to ticks carrying the deadly B. canis pathogen. Over the following weeks, meticulous blood tests were conducted to monitor the presence of the pathogen.

Remarkably, while all placebo-treated dogs showed signs of babesiosis and tested positive for B. canis, the dogs treated with Simparica Trio remained symptom-free and clear of the pathogen. This striking result demonstrated a 100% efficacy rate in preventing the transmission of canine babesiosis, marking a significant milestone in veterinary medicine.

This study not only confirms the effectiveness of Simparica Trio in safeguarding dogs from a lethal tick-borne disease but also highlights the importance of proactive prevention measures. As the threat of vector-borne pathogens continues to rise, this treatment stands as a beacon of hope, offering complete protection for our four-legged friends against the ravages of Babesia canis.

Read full article here: https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-023-06115-2